Gilead Sciences (CHIX:GISD) 1-Year Share Buyback Ratio : 0.00% (As of Dec. 2024 )

View and export this data going back to 2023. Start your Free Trial

What is Gilead Sciences 1-Year Share Buyback Ratio?

Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.

1-Year Share Buyback Ratio measures the proportion of a company's outstanding shares repurchased over the past year, calculated as the percentage change in shares outstanding from the previous year to the current year. A positive ratio may indicates share buybacks over the period, while a zero or negative ratio suggests no buybacks or potential share issuance. Gilead Sciences's current 1-Year Share Buyback Ratio was 0.00%.

CHIX:GISd's 1-Year Share Buyback Ratio is not ranked ^*
in the Drug Manufacturers industry.
Industry Median: -1.9
* Ranked among companies with meaningful 1-Year Share Buyback Ratio only.

Competitive Comparison of Gilead Sciences's 1-Year Share Buyback Ratio

For the Drug Manufacturers - General subindustry, Gilead Sciences's 1-Year Share Buyback Ratio, along with its competitors' market caps and 1-Year Share Buyback Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Gilead Sciences's 1-Year Share Buyback Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Gilead Sciences's 1-Year Share Buyback Ratio distribution charts can be found below:

* The bar in red indicates where Gilead Sciences's 1-Year Share Buyback Ratio falls into.

Save Embed

;

Save Embed

;

Gilead Sciences 1-Year Share Buyback Ratio Calculation

Gilead Sciences's 1-Year Share Buyback Ratio for the quarter that ended in Dec. 2024 is calculated as

1-Year Share Buyback Ratio	=	(Shares Outstanding (EOP) (Dec. 2023 )	-	Shares Outstanding (EOP) (Dec. 2024 ))	/	Shares Outstanding (EOP) (Dec. 2023 )
	=	(1246.042	-	1246.266)	/	1246.042
	=	-0.0%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Gilead Sciences (CHIX:GISd) 1-Year Share Buyback Ratio Explanation

A positive ratio may indicates share buybacks over the period, while a zero or negative ratio suggests no buybacks or potential share issuance.

Be Aware

Investors usually like share buybacks. But as pointed by Warren Buffett, only if a company buys back shares at the prices below the stock's intrinsic value, it rewards remaining shareholders. If a company buys its overvalued stocks back, it destroys shareholder value.

Gilead Sciences 1-Year Share Buyback Ratio Related Terms

Gilead Sciences Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Gilead Sciences Inc (CHIX:GISd) » Definitions » 1-Year Share Buyback Ratio

Comparable Companies

Traded in Other Exchanges

GILD:USA GILD:Peru GILD:Mexico 1GILD:Italy 0QYQ:UK GIS:Germany GIS:Germany GIS:Germany GIS:Germany GILD34:Brazil GILD:Austria GILD:Argentina

Address

333 Lakeside Drive, Foster City, CA, USA, 94404

Website

https://www.gilead.com

Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).

Gilead Sciences Headlines

No Headlines